CFTR and hereditary disease: The concept of readthrough therapy for genetic diseases was first demonstrated in 1996 by Howard et al., who showed that aminoglycosides could induce readthrough and restore functional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) by targeting the p.Gly542* mutation [21].